Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Curtis

Rheumatology Birmingham, AL Medical Doctor

NPI 1669415725 CMS profile 211411

619 19Th Street South, Birmingham, AL 35233

Open in the dashboard

General payments

$612,072

342 records reported · program years 2019–2025

Research payments

$104,243

Paid to them · 75 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,994,434 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeffrey Curtis of Birmingham, AL is reported in the CMS Open Payments database as having received $612,072 across 342 general payments and $104,243 in research payments paid to them. Separately, studies naming them as principal investigator received $16,994,434 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $49,770 28
2025 Research $7,670 4
2024 General $36,810 40
2024 Research $5,410 4
2023 General $124,701 85
2023 Research $8,430 4
2022 General $56,620 34
2022 Research $7,920 7
2021 General $62,470 22
2021 Research $25,384 18
2020 General $120,737 52
2020 Research $28,547 20
2019 General $160,964 81
2019 Research $20,882 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Curtis
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Jeffrey Curtis were reported at $49,770. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Jeffrey Curtis Rheumatology median Middle half National median
2019 $160,964 $744 $153–$2,687 $163
2020 $120,737 $462 $98–$2,027 $114
2021 $62,470 $531 $101–$2,153 $132
2022 $56,620 $627 $125–$2,303 $149
2023 $124,701 $741 $145–$2,524 $160
2024 $36,810 $830 $166–$2,660 $164
2025 $49,770 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $77,494 43 payments
  2. Radius Health, Inc. $63,939 19 payments
  3. Pfizer Inc. $59,925 21 payments
  4. Janssen Scientific Affairs, LLC $56,299 26 payments
  5. Genzyme Corporation $52,934 22 payments
  6. Eli Lilly and Company $45,129 19 payments
  7. AbbVie, Inc. $37,218 24 payments
  8. GlaxoSmithKline, LLC. $31,037 22 payments
  9. Moderna TX, Inc. $24,194 16 payments
  10. Ucb SA $18,966 5 payments
  11. Other $144,936 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $515,341 146 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,518 38 payments
  3. Travel and Lodging $36,544 59 payments
  4. Honoraria $13,725 5 payments
  5. Food and Beverage $3,996 85 payments
  6. Education $3,947 9 payments
Products named General payments · program years 2019–2025
  1. XELJANZ $52,300 18 payments
  2. REMICADE $45,966 13 payments
  3. KEVZARA $45,390 16 payments
  4. SIMPONI ARIA $40,384 12 payments
  5. EVENITY $33,786 19 payments
  6. TREMFYA $32,937 34 payments
  7. Moderna Covid-19 Vaccine $24,194 16 payments
  8. Enbrel $19,852 4 payments
  9. Prolia $17,293 13 payments
  10. RINVOQ $16,751 13 payments
  11. Other $111,518 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $59,550 40 payments
  2. UCB, Inc. $15,220 8 payments
  3. Amgen Inc. $13,465 6 payments
  4. TissueTech, Inc. $7,789 3 payments
  5. Sanofi-Aventis U.S. LLC $5,115 13 payments
  6. Genzyme Corporation $3,105 5 payments

Records

417 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record